Share this:
18
With CBD maker CV Sciences (CVS) joining Hemp Inc. last month as the second target of a federal fraud case in the USA, the question resurfaces: How much damage to the industry’s image? Critics have long railed against the entire penny-stock empire-building “strategy” (see: “Wolf of Wall Street” and tack on the subheadline: “Hemp investing for suckers”).